Omixon is a global molecular diagnostics company, empowering clinical labs with technologies to improve patient outcomes by commercializing disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
In Q3, Omixon will be launching HLA Explore to replace Target HLA as our primary research use software product for HLA Genotyping by NGS. HLA Explore is designed for genetics/genomics researchers and the analysis and interpretation of any NGS data. …more
We all need a little reassurance sometimes… In the past few years Next Generation Sequencing has conquered immunology labs all around the world and is actively used in both research and diagnostics. But how was it possible to develop and …more